Previous 10 | Next 10 |
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,...
Patent challenge initiated by Bausch Health Companies NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug product...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead Investors will have their eyes on economic reports covering construction spending, manufacturing a...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Sol-Gel Technologies (NASDAQ: SLGL ) : Q2 GAAP EPS of -$0.31 beats by $0.03 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020 Top-line generic product revenue of $1.1 million in 2Q 2020 Launch of additional generic product expected in 2Q 2021 NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) --...
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for...
NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Sol...
Sol-Gel Technologies (NASDAQ: SLGL ) has entered into collaborative agreements with Perrigo Company (NYSE: PRGO ), for the development, manufacturing and commercialization of three new, generic product candidates. More news on: Sol-Gel Technologies Ltd., Perrigo Company plc, Bausch Healt...
NESS ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that it ...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...